LitCovid-sample-Enju  

PMC:7228307 JSONTXT 37 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T0 57351-57354 DT denotes The
T1 57355-57365 NN denotes expression
T2 57366-57368 IN denotes of
T3 57369-57376 NN denotes FcγRIIb
T4 57377-57379 IN denotes on
T5 57380-57384 NNP denotes LSEC
T6 57385-57388 CC denotes and
T7 57389-57392 PRP-DOLLAR- denotes its
T8 57393-57399 NN denotes action
T9 57400-57402 IN denotes in
T10 57403-57406 DT denotes the
T11 57407-57417 NN denotes “sweeping”
T12 57418-57420 CC denotes or
T13 57421-57428 NN denotes removal
T14 57429-57431 IN denotes of
T15 57432-57437 JJ denotes small
T16 57438-57444 JJ denotes immune
T17 57445-57454 NNS denotes complexes
T18 57455-57458 VBZ denotes has
T19 57459-57465 VBN denotes opened
T20 57466-57468 RP denotes up
T21 57469-57472 JJ denotes new
T22 57473-57486 NNS denotes possibilities
T23 57487-57490 IN denotes for
T24 57491-57494 DT denotes the
T25 57495-57506 NN denotes application
T26 57507-57509 IN denotes of
T27 57510-57527 VBG denotes FcγRIIb‐enhancing
T28 57528-57544 NN denotes modifications.17
T29 57545-57555 NNS denotes Antibodies
T30 57556-57558 CC denotes or
T31 57559-57561 NN denotes Fc
T32 57562-57568 NN denotes fusion
T33 57569-57577 NNS denotes proteins
T34 57577-57578 -COMMA- denotes ,
T35 57579-57584 WP-DOLLAR- denotes whose
T36 57585-57592 JJ denotes primary
T37 57593-57596 NN denotes MOA
T38 57597-57599 VBZ denotes is
T39 57600-57603 DT denotes the
T40 57604-57618 NN denotes neutralization
T41 57619-57621 IN denotes of
T42 57622-57629 JJ denotes soluble
T43 57630-57639 NNS denotes molecules
T44 57640-57644 JJ denotes such
T45 57645-57647 IN denotes as
T46 57648-57651 NN denotes IgE
T47 57652-57654 CC denotes or
T48 57655-57664 NNS denotes cytokines
T49 57664-57665 -COMMA- denotes ,
T50 57666-57669 VBP denotes are
T51 57670-57682 RB denotes particularly
T52 57683-57693 JJ denotes attractive
T53 57694-57704 NNS denotes candidates
T54 57705-57708 IN denotes for
T55 57709-57713 DT denotes this
T56 57714-57722 NN denotes approach
T57 57724-57740 NN denotes Proof‐of‐concept
T58 57741-57744 IN denotes for
T59 57745-57749 DT denotes this
T60 57750-57758 NN denotes strategy
T61 57759-57762 VBZ denotes has
T62 57763-57767 VBN denotes been
T63 57768-57780 VBN denotes demonstrated
T64 57781-57783 IN denotes in
T65 57784-57796 JJ denotes experimental
T66 57797-57806 NN denotes models.48
T67 57807-57813 RB denotes Indeed
T68 57813-57814 -COMMA- denotes ,
T69 57815-57819 DT denotes this
T70 57820-57823 MD denotes may
T71 57824-57826 VB denotes be
T72 57827-57828 DT denotes a
T73 57829-57840 JJ denotes significant
T74 57841-57850 NN denotes component
T75 57851-57853 IN denotes of
T76 57854-57857 DT denotes the
T77 57858-57863 JJ denotes rapid
T78 57864-57877 NN denotes disappearance
T79 57878-57880 IN denotes of
T80 57881-57884 NN denotes IgE
T81 57885-57889 IN denotes from
T82 57890-57893 DT denotes the
T83 57894-57905 NN denotes circulation
T84 57906-57908 IN denotes of
T85 57909-57917 NNS denotes patients
T86 57918-57925 VBN denotes treated
T87 57926-57930 IN denotes with
T88 57931-57934 DT denotes the
T89 57935-57943 NN denotes anti‐IgE
T90 57944-57952 NN denotes XmAb7195
T91 57953-57963 VBG denotes containing
T92 57964-57967 DT denotes the
T93 57968-57975 NN denotes FcγRIIb
T94 57976-57985 VBG denotes enhancing
T95 57986-57992 NNP denotes “SELF”
T96 57993-58006 NNS denotes modifications
T97 58006-58007 -COMMA- denotes ,
T98 58008-58010 IN denotes as
T99 58011-58020 VBN denotes described
T100 58021-58031 RB denotes previously
T101 58034-58040 JJ denotes Immune
T102 58041-58048 NN denotes agonism
T103 58049-58056 IN denotes through
T104 58057-58061 NN denotes FcγR
T105 58062-58073 NN denotes scaffolding
T106 58074-58083 JJ denotes Agonistic
T107 58084-58088 NNS denotes mAbs
T108 58089-58095 VBP denotes induce
T109 58096-58105 NNS denotes responses
T110 58106-58108 IN denotes in
T111 58109-58115 NN denotes target
T112 58116-58121 NNS denotes cells
T113 58122-58124 IN denotes by
T114 58125-58136 VBG denotes stimulating
T115 58137-58146 NN denotes signaling
T116 58147-58149 IN denotes of
T117 58150-58155 PRP-DOLLAR- denotes their
T118 58156-58165 JJ denotes molecular
T119 58166-58172 NN denotes target
T120 58174-58183 RB denotes Typically
T121 58183-58184 -COMMA- denotes ,
T122 58185-58189 DT denotes this
T123 58190-58192 VBZ denotes is
T124 58193-58195 TO denotes to
T125 58196-58202 CC denotes either
T126 58203-58210 VB denotes enhance
T127 58211-58220 NN denotes antitumor
T128 58221-58229 NN denotes immunity
T129 58230-58232 IN denotes by
T130 58233-58241 VBG denotes engaging
T131 58242-58255 JJ denotes costimulatory
T132 58256-58265 NNS denotes molecules
T133 58266-58268 IN denotes on
T134 58269-58287 JJ denotes antigen‐presenting
T135 58288-58293 NNS denotes cells
T136 58294-58296 CC denotes or
T137 58297-58298 NN denotes T
T138 58299-58304 NNS denotes cells
T139 58305-58306 -LRB- denotes (
T140 58306-58310 FW denotes i.e.
T141 58311-58315 NN denotes CD40
T142 58315-58316 -COMMA- denotes ,
T143 58317-58322 NN denotes 4‐1BB
T144 58322-58323 -COMMA- denotes ,
T145 58324-58328 NN denotes OX40
T146 58328-58329 -RRB- denotes )
T147 58330-58332 CC denotes or
T148 58333-58340 VB denotes promote
T149 58341-58350 NN denotes apoptosis
T150 58351-58353 IN denotes by
T151 58354-58362 VBG denotes engaging
T152 58363-58368 NN denotes death
T153 58369-58378 NNS denotes receptors
T154 58379-58381 IN denotes on
T155 58382-58388 NN denotes cancer
T156 58389-58394 NNS denotes cells
T157 58395-58396 -LRB- denotes (
T158 58396-58400 FW denotes i.e.
T159 58401-58404 NN denotes DR4
T160 58404-58405 -COMMA- denotes ,
T161 58406-58409 NN denotes DR5
T162 58409-58410 -COMMA- denotes ,
T163 58411-58414 NN denotes Fas
T164 58414-58415 -RRB- denotes )
T165 58420-58423 DT denotes The
T166 58424-58428 NN denotes role
T167 58429-58431 IN denotes of
T168 58432-58436 NN denotes FcγR
T169 58437-58439 IN denotes in
T170 58440-58443 DT denotes the
T171 58444-58450 NN denotes action
T172 58451-58453 IN denotes of
T173 58454-58459 DT denotes these
T174 58460-58465 NNS denotes types
T175 58466-58468 IN denotes of
T176 58469-58473 NNS denotes mAbs
T177 58474-58481 VBZ denotes appears
T178 58482-58484 TO denotes to
T179 58485-58487 VB denotes be
T180 58488-58497 RB denotes primarily
T181 58498-58500 IN denotes as
T182 58501-58502 DT denotes a
T183 58503-58511 NN denotes scaffold
T184 58513-58520 NN denotes FcγRIIb
T185 58521-58523 VBZ denotes is
T186 58524-58529 RB denotes often
T187 58530-58533 DT denotes the
T188 58534-58545 JJ denotes predominate
T189 58546-58554 NN denotes receptor
T190 58555-58563 VBN denotes involved
T191 58564-58567 CC denotes and
T192 58568-58571 DT denotes the
T193 58572-58578 NN denotes extent
T194 58579-58581 IN denotes of
T195 58582-58585 PRP-DOLLAR- denotes its
T196 58586-58597 NN denotes involvement
T197 58598-58600 VBZ denotes is
T198 58601-58608 JJ denotes complex
T199 58610-58612 IN denotes In
T200 58613-58616 DT denotes the
T201 58617-58621 NN denotes case
T202 58622-58624 IN denotes of
T203 58625-58629 NN denotes CD40
T204 58629-58630 -COMMA- denotes ,
T205 58631-58634 DT denotes the
T206 58635-58641 NN denotes degree
T207 58642-58644 IN denotes of
T208 58645-58652 NN denotes FcγRIIb
T209 58653-58664 NN denotes scaffolding
T210 58665-58672 NN denotes potency
T211 58673-58675 VBZ denotes is
T212 58676-58682 VBN denotes linked
T213 58683-58685 TO denotes to
T214 58686-58689 DT denotes the
T215 58690-58697 NN denotes epitope
T216 58698-58706 NN denotes location
T217 58707-58709 IN denotes of
T218 58710-58713 DT denotes the
T219 58714-58723 VBG denotes targeting
T220 58724-58727 NN denotes mAb
T221 58728-58732 IN denotes with
T222 58733-58740 JJR denotes greater
T223 58741-58748 NN denotes potency
T224 58749-58753 VBN denotes seen
T225 58754-58757 IN denotes for
T226 58758-58766 NN denotes membrane
T227 58767-58775 JJ denotes proximal
T228 58776-58787 NN denotes epitopes.43
T229 58787-58788 -COMMA- denotes ,
T230 58789-58792 CD denotes 117
T231 58793-58795 PRP denotes It
T232 58796-58798 VBZ denotes is
T233 58799-58803 RB denotes also
T234 58804-58814 JJ denotes noteworthy
T235 58815-58819 IN denotes that
T236 58820-58829 VBG denotes depending
T237 58830-58832 IN denotes on
T238 58833-58836 DT denotes the
T239 58837-58844 NN denotes epitope
T240 58845-58853 NN denotes location
T241 58853-58854 -COMMA- denotes ,
T242 58855-58858 DT denotes the
T243 58859-58870 NN denotes scaffolding
T244 58871-58873 IN denotes of
T245 58874-58883 NN denotes anti‐CD40
T246 58884-58888 NNS denotes mAbs
T247 58889-58892 MD denotes may
T248 58893-58900 VB denotes convert
T249 58901-58911 NN denotes antagonist
T250 58912-58916 NNS denotes mAbs
T251 58917-58919 TO denotes to
T252 58920-58929 JJ denotes agonistic
T253 58931-58942 NN denotes Engineering
T254 58943-58945 IN denotes of
T255 58946-58949 DT denotes the
T256 58950-58954 NN denotes IgG1
T257 58955-58957 NN denotes Fc
T258 58958-58964 NN denotes region
T259 58965-58968 IN denotes for
T260 58969-58977 VBN denotes enhanced
T261 58978-58984 CC denotes and/or
T262 58985-58993 JJ denotes specific
T263 58994-59001 NN denotes binding
T264 59002-59004 TO denotes to
T265 59005-59012 NN denotes FcγRIIb
T266 59013-59016 MD denotes can
T267 59017-59024 RB denotes greatly
T268 59025-59032 VB denotes improve
T269 59033-59042 JJ denotes agonistic
T270 59043-59054 NN denotes function.72
T271 59054-59055 -COMMA- denotes ,
T272 59056-59059 CD denotes 118
T273 59059-59060 -COMMA- denotes ,
T274 59061-59064 CD denotes 119
T275 59064-59065 -COMMA- denotes ,
T276 59066-59069 CD denotes 120
T277 59070-59074 JJ denotes Such
T278 59075-59084 NNS denotes mutations
T279 59085-59092 VBD denotes induced
T280 59093-59106 RB denotes significantly
T281 59107-59114 JJR denotes greater
T282 59115-59124 JJ denotes agonistic
T283 59125-59133 NN denotes activity
T284 59134-59136 IN denotes in
T285 59137-59139 DT denotes an
T286 59140-59148 NN denotes anti‐DR5
T287 59149-59154 NN denotes model
T288 59155-59162 IN denotes through
T289 59163-59172 VBN denotes increased
T290 59173-59182 NN denotes induction
T291 59183-59185 IN denotes of
T292 59186-59195 JJ denotes apoptotic
T293 59196-59201 NN denotes death
T294 59202-59205 CC denotes and
T295 59206-59215 VBD denotes decreased
T296 59216-59221 NN denotes tumor
T297 59222-59228 NN denotes growth
T298 59229-59237 VBN denotes compared
T299 59238-59242 IN denotes with
T300 59243-59253 JJ denotes unmodified
T301 59254-59262 NN denotes IgG1.121
T302 59263-59266 DT denotes The
T303 59267-59273 NNP denotes “SELF”
T304 59274-59287 NNS denotes modifications
T305 59288-59292 WDT denotes that
T306 59293-59305 RB denotes dramatically
T307 59306-59309 CC denotes and
T308 59310-59321 RB denotes selectively
T309 59322-59330 VBP denotes increase
T310 59331-59339 NN denotes affinity
T311 59340-59343 IN denotes for
T312 59344-59351 NN denotes FcγRIIb
T313 59352-59356 VBP denotes have
T314 59357-59361 RB denotes also
T315 59362-59366 VBN denotes been
T316 59367-59371 VBN denotes used
T317 59372-59374 TO denotes to
T318 59375-59382 VB denotes enhance
T319 59383-59389 JJ denotes immune
T320 59390-59397 NN denotes agonism
T321 59398-59400 IN denotes in
T322 59401-59403 DT denotes an
T323 59404-59413 NN denotes anti‐OX40
T324 59414-59423 NN denotes model.122
T325 59424-59427 DT denotes The
T326 59428-59444 NN denotes incorporation of
T327 59445-59448 DT denotes the
T328 59449-59450 -DQS- denotes "
T329 59450-59453 NN denotes V12
T330 59453-59454 '' denotes "
T331 59455-59457 NN denotes Fc
T332 59458-59467 NNS denotes mutations
T333 59468-59472 IN denotes into
T334 59473-59477 NN denotes IgG1
T335 59478-59490 RB denotes specifically
T336 59491-59498 VBP denotes enhance
T337 59499-59506 NN denotes FcγRIIb
T338 59507-59518 NN denotes interaction
T339 59519-59527 RB denotes 200‐fold
T340 59527-59528 -COMMA- denotes ,
T341 59529-59539 VBG denotes conferring
T342 59540-59543 DT denotes the
T343 59544-59552 VBN denotes enhanced
T344 59553-59562 JJ denotes agonistic
T345 59563-59571 NN denotes activity
T346 59572-59574 IN denotes of
T347 59575-59577 DT denotes an
T348 59578-59588 NN denotes anti‐CD137
T349 59589-59597 NN denotes antibody
T350 59598-59601 CC denotes and
T351 59602-59604 DT denotes an
T352 59605-59614 NN denotes anti‐OX40
T353 59615-59622 NN denotes mAb.115
T354 59622-59623 -COMMA- denotes ,
T355 59624-59627 CD denotes 122
T356 59629-59635 NNP denotes Future
T357 59636-59647 NNP denotes Engineering
T358 59648-59658 NNPS denotes Strategies
T359 59659-59669 JJ denotes Monoclonal
T360 59670-59680 NNS denotes antibodies
T361 59681-59684 VBP denotes are
T362 59685-59691 JJ denotes potent
T363 59692-59704 NNS denotes therapeutics
T364 59705-59707 IN denotes in
T365 59708-59709 DT denotes a
T366 59710-59716 NN denotes number
T367 59717-59719 IN denotes of
T368 59720-59727 JJ denotes chronic
T369 59728-59730 CC denotes or
T370 59731-59735 RB denotes once
T371 59736-59745 JJ denotes incurable
T372 59746-59754 NNS denotes diseases
T373 59756-59763 RB denotes However
T374 59763-59764 -COMMA- denotes ,
T375 59765-59770 EX denotes there
T376 59771-59773 VBZ denotes is
T377 59774-59779 RB denotes still
T378 59780-59789 JJ denotes extensive
T379 59790-59795 JJ denotes unmet
T380 59796-59804 JJ denotes clinical
T381 59805-59809 NN denotes need
T382 59810-59812 RB denotes as
T383 59813-59817 RB denotes well
T384 59818-59820 IN denotes as
T385 59821-59833 JJ denotes considerable
T386 59834-59838 NN denotes room
T387 59839-59842 IN denotes for
T388 59843-59854 NN denotes improvement
T389 59855-59857 IN denotes in
T390 59858-59862 JJ denotes many
T391 59863-59871 VBG denotes existing
T392 59872-59884 NNS denotes therapeutics
T393 59886-59893 JJ denotes Further
T394 59894-59907 NN denotes understanding
T395 59908-59910 IN denotes of
T396 59911-59914 WRB denotes how
T397 59915-59923 NN denotes antibody
T398 59924-59933 NN denotes structure
T399 59934-59941 VBZ denotes affects
T400 59942-59946 NN denotes FcγR
T401 59947-59955 NN denotes function
T402 59956-59958 VBZ denotes is
T403 59959-59968 JJ denotes essential
T404 59969-59972 IN denotes for
T405 59973-59979 JJ denotes future
T406 59980-59991 NN denotes development
T407 59992-59994 IN denotes of
T408 59995-59999 RBR denotes more
T409 60000-60006 JJ denotes potent
T410 60007-60010 CC denotes and
T411 60011-60020 JJ denotes effective
T412 60021-60025 NNS denotes mAbs
T413 60027-60034 RB denotes Already
T414 60034-60035 -COMMA- denotes ,
T415 60036-60047 NN denotes engineering
T416 60048-60050 IN denotes of
T417 60051-60054 DT denotes the
T418 60055-60058 NN denotes IgG
T419 60059-60061 NN denotes Fc
T420 60062-60065 CC denotes and
T421 60066-60069 PRP-DOLLAR- denotes its
T422 60070-60076 NN denotes glycan
T423 60077-60080 VBZ denotes has
T424 60081-60087 VBN denotes proved
T425 60088-60089 DT denotes a
T426 60090-60096 JJ denotes potent
T427 60097-60100 CC denotes and
T428 60101-60110 JJ denotes effective
T429 60111-60119 NN denotes approach
T430 60120-60123 IN denotes for
T431 60124-60134 VBG denotes increasing
T432 60135-60138 DT denotes the
T433 60139-60147 JJ denotes clinical
T434 60148-60161 NN denotes effectiveness
T435 60161-60162 -COMMA- denotes ,
T436 60163-60173 JJ denotes functional
T437 60174-60185 NN denotes specificity
T438 60186-60189 CC denotes and
T439 60190-60196 NN denotes safety
T440 60197-60199 IN denotes of
T441 60200-60211 JJ denotes therapeutic
T442 60212-60216 NNS denotes mAbs
T443 60217-60220 CC denotes and
T444 60221-60223 VBZ denotes is
T445 60224-60226 DT denotes an
T446 60227-60235 VBG denotes emerging
T447 60236-60243 NN denotes pathway
T448 60244-60246 TO denotes to
T449 60247-60250 DT denotes the
T450 60251-60262 NN denotes development
T451 60263-60265 IN denotes of
T452 60266-60269 DT denotes the
T453 60270-60280 NN denotes “next‐gen”
T454 60281-60293 NNS denotes therapeutics
T455 60295-60301 JJ denotes Future
T456 60302-60312 NNS denotes directions
T457 60313-60315 IN denotes in
T458 60316-60319 DT denotes the
T459 60320-60331 NN denotes development
T460 60332-60335 CC denotes and
T461 60336-60339 NN denotes use
T462 60340-60342 IN denotes of
T463 60343-60354 JJ denotes therapeutic
T464 60355-60365 NNS denotes antibodies
T465 60366-60372 MD denotes should
T466 60373-60385 RB denotes increasingly
T467 60386-60391 VB denotes mimic
T468 60392-60398 JJ denotes normal
T469 60399-60409 JJ denotes protective
T470 60410-60418 NN denotes antibody
T471 60419-60428 NNS denotes responses
T472 60428-60429 -COMMA- denotes ,
T473 60430-60435 WDT denotes which
T474 60436-60439 VBP denotes are
T475 60440-60450 JJ denotes polyclonal
T476 60451-60454 CC denotes and
T477 60455-60463 VBN denotes elicited
T478 60464-60466 IN denotes in
T479 60467-60470 DT denotes the
T480 60471-60478 NN denotes context
T481 60479-60481 IN denotes of
T482 60482-60488 JJ denotes innate
T483 60489-60497 NN denotes receptor
T484 60498-60508 NN denotes engagement
T485 60509-60514 WDT denotes which
T486 60515-60523 VBZ denotes includes
T487 60524-60527 DT denotes the
T488 60528-60531 NNS denotes FcR
T489 60532-60534 RB denotes as
T490 60535-60539 RB denotes well
T491 60540-60542 IN denotes as
T492 60543-60548 JJ denotes other
T493 60549-60559 RB denotes powerfully
T494 60560-60570 JJ denotes responsive
T495 60571-60578 NNS denotes systems
T496 60579-60588 VBG denotes including
T497 60589-60592 DT denotes the
T498 60593-60602 JJ denotes Toll‐like
T499 60603-60612 NNS denotes receptors
T500 60613-60616 CC denotes and
T501 60617-60627 NN denotes complement
T502 60628-60637 NNS denotes receptors
T503 60639-60650 RB denotes Furthermore
T504 60650-60651 -COMMA- denotes ,
T505 60652-60655 DT denotes the
T506 60656-60661 JJ denotes mixed
T507 60662-60670 NN denotes subclass
T508 60671-60677 NN denotes nature
T509 60678-60680 IN denotes of
T510 60681-60686 DT denotes these
T511 60687-60693 JJ denotes normal
T512 60694-60702 NN denotes antibody
T513 60703-60712 NNS denotes responses
T514 60713-60721 VBZ denotes suggests
T515 60722-60726 IN denotes that
T516 60727-60740 NNS denotes circumstances
T517 60741-60744 MD denotes may
T518 60745-60750 VB denotes arise
T519 60751-60753 IN denotes in
T520 60754-60765 JJ denotes therapeutic
T521 60766-60776 NNS denotes strategies
T522 60777-60782 WRB denotes where
T523 60783-60788 EX denotes there
T524 60789-60791 VBZ denotes is
T525 60792-60797 NN denotes value
T526 60798-60800 IN denotes in
T527 60801-60807 VBG denotes having
T528 60808-60818 RB denotes distinctly
T529 60819-60827 VBN denotes modified
T530 60828-60831 NNS denotes Fcs
T531 60832-60835 IN denotes for
T532 60836-60839 DT denotes the
T533 60840-60847 JJ denotes nuanced
T534 60848-60858 NN denotes engagement
T535 60859-60861 IN denotes of
T536 60862-60871 JJ denotes different
T537 60872-60876 NN denotes FcγR
T538 60877-60883 NN denotes family
T539 60884-60891 NNS denotes members
T540 60893-60903 NNS denotes Treatments
T541 60904-60914 VBG denotes comprising
T542 60915-60923 JJ denotes multiple
T543 60924-60928 NNS denotes mAbs
T544 60929-60932 CC denotes and
T545 60933-60939 JJ denotes immune
T546 60940-60950 NNS denotes stimulants
T547 60951-60954 VBP denotes are
T548 60955-60960 IN denotes under
T549 60961-60974 NN denotes investigation
T550 60975-60977 IN denotes in
T551 60978-60988 JJ denotes infectious
T552 60989-60996 NN denotes disease
T553 60997-61000 IN denotes for
T554 61001-61015 NN denotes neutralization
T555 61016-61024 NN denotes coverage
T556 61025-61027 IN denotes of
T557 61028-61035 JJ denotes variant
T558 61036-61043 NNS denotes strains
T559 61045-61051 RB denotes Indeed
T560 61051-61052 -COMMA- denotes ,
T561 61053-61057 PDT denotes such
T562 61058-61060 DT denotes an
T563 61061-61069 NN denotes approach
T564 61070-61073 MD denotes may
T565 61074-61076 VB denotes be
T566 61077-61081 RBS denotes most
T567 61082-61091 JJ denotes effective
T568 61092-61094 IN denotes in
T569 61095-61103 VBG denotes emerging
T570 61104-61114 JJ denotes infectious
T571 61115-61122 NN denotes disease
T572 61123-61127 JJ denotes such
T573 61128-61130 IN denotes as
T574 61131-61137 JJ denotes severe
T575 61138-61143 JJ denotes acute
T576 61144-61155 JJ denotes respiratory
T577 61156-61164 NN denotes syndrome
T578 61165-61176 NN denotes coronavirus
T579 61177-61178 CD denotes 2
T580 61179-61180 -LRB- denotes (
T581 61180-61190 NN denotes SARS‐CoV‐2
T582 61190-61191 -RRB- denotes )
T583 61192-61201 NN denotes infection
T584 61203-61206 DT denotes The
T585 61207-61210 NN denotes use
T586 61211-61213 IN denotes of
T587 61214-61222 JJ denotes multiple
T588 61223-61227 NNS denotes mAbs
T589 61228-61236 VBN denotes tailored
T590 61237-61240 IN denotes for
T591 61241-61249 JJ denotes distinct
T592 61250-61258 NN denotes effector
T593 61259-61268 NNS denotes functions
T594 61269-61272 CC denotes and
T595 61273-61282 VBG denotes targeting
T596 61283-61292 JJ denotes different
T597 61293-61301 NNS denotes epitopes
T598 61302-61306 MD denotes will
T599 61307-61315 VB denotes maximize
T600 61316-61319 DT denotes the
T601 61320-61331 NN denotes opportunity
T602 61332-61335 IN denotes for
T603 61336-61347 NN denotes cocktailing
T604 61348-61350 IN denotes of
T605 61351-61359 NN denotes effector
T606 61360-61369 NNS denotes functions
T607 61370-61372 IN denotes in
T608 61373-61382 JJ denotes different
T609 61383-61388 NNS denotes types
T610 61389-61391 IN denotes of
T611 61392-61400 NNS denotes diseases
T612 61402-61408 RB denotes Indeed
T613 61408-61409 -COMMA- denotes ,
T614 61410-61412 IN denotes in
T615 61413-61414 DT denotes a
T616 61415-61420 JJ denotes small
T617 61421-61424 CC denotes but
T618 61425-61437 JJ denotes contemporary
T619 61438-61445 NN denotes example
T620 61446-61453 IN denotes outside
T621 61454-61456 IN denotes of
T622 61457-61467 JJ denotes infectious
T623 61468-61475 NN denotes disease
T624 61475-61476 -COMMA- denotes ,
T625 61477-61480 DT denotes the
T626 61481-61493 NNP denotes FDA‐approved
T627 61494-61505 NN denotes combination
T628 61506-61508 IN denotes in
T629 61509-61523 NN denotes adenocarcinoma
T630 61524-61531 NN denotes therapy
T631 61532-61536 VBZ denotes uses
T632 61537-61538 DT denotes a
T633 61539-61547 NN denotes cocktail
T634 61548-61550 IN denotes of
T635 61551-61554 CD denotes two
T636 61555-61559 NNS denotes mAbs
T637 61559-61560 -COMMA- denotes ,
T638 61561-61571 NN denotes pertuzumab
T639 61572-61575 CC denotes and
T640 61576-61587 NN denotes trastuzumab
T641 61587-61588 -COMMA- denotes ,
T642 61589-61596 IN denotes against
T643 61597-61605 NN denotes Her2.123
T644 61606-61612 RB denotes Rather
T645 61613-61617 IN denotes than
T646 61618-61621 CD denotes one
T647 61622-61626 NN denotes type
T648 61627-61629 IN denotes of
T649 61630-61632 NN denotes Fc
T650 61633-61635 TO denotes to
T651 61636-61643 VB denotes conquer
T652 61644-61647 DT denotes all
T653 61647-61648 -COMMA- denotes ,
T654 61649-61652 DT denotes the
T655 61653-61661 JJ denotes combined
T656 61662-61665 NN denotes use
T657 61666-61668 IN denotes of
T658 61669-61682 RB denotes appropriately
T659 61683-61691 VBN denotes selected
T660 61692-61696 NNS denotes mAbs
T661 61697-61702 WP-DOLLAR- denotes whose
T662 61703-61713 JJ denotes individual
T663 61714-61724 NNS denotes components
T664 61725-61728 VBP denotes are
T665 61729-61737 VBN denotes enhanced
T666 61738-61741 IN denotes for
T667 61742-61745 DT denotes the
T668 61746-61756 NN denotes engagement
T669 61757-61759 IN denotes of
T670 61760-61769 JJ denotes different
T671 61770-61774 NN denotes FcγR
T672 61775-61782 NNS denotes members
T673 61783-61786 MD denotes may
T674 61787-61794 VB denotes utilize
T675 61795-61803 JJ denotes multiple
T676 61804-61814 NNS denotes components
T677 61815-61817 IN denotes of
T678 61818-61821 DT denotes the
T679 61822-61830 NN denotes spectrum
T680 61831-61833 IN denotes of
T681 61834-61842 NN denotes effector
T682 61843-61852 NNS denotes responses
T683 61853-61855 IN denotes on
T684 61856-61861 NN denotes offer
T685 61862-61864 IN denotes by
T686 61865-61868 DT denotes the
T687 61869-61875 JJ denotes immune
T688 61876-61882 NN denotes system
T689 61884-61888 JJ denotes Such
T690 61889-61899 NN denotes “next‐gen”
T691 61900-61909 NNS denotes biologics
T692 61910-61914 MD denotes will
T693 61915-61920 VB denotes begin
T694 61921-61923 TO denotes to
T695 61924-61931 VB denotes realize
T696 61932-61935 DT denotes the
T697 61936-61940 JJ denotes full
T698 61941-61950 NN denotes potential
T699 61951-61953 IN denotes of
T700 61954-61967 JJ denotes FcγR‐mediated
T701 61968-61976 NN denotes antibody
T702 61977-61983 JJ denotes immune
T703 61984-61996 NNS denotes therapeutics
T704 61997-62000 CC denotes and
T705 62001-62006 VB denotes offer
T706 62007-62023 JJ denotes transformational
T707 62024-62030 NN denotes change
T708 62031-62034 IN denotes for
T709 62035-62038 DT denotes the
T710 62039-62048 NN denotes treatment
T711 62049-62051 IN denotes of
T712 62052-62063 JJ denotes intractable
T713 62064-62067 CC denotes and
T714 62068-62077 JJ denotes incurable
T715 62078-62086 NNS denotes diseases
T716 62089-62097 NN denotes Conflict
T717 62098-62100 IN denotes of
T718 62101-62109 NN denotes Interest
T719 62110-62114 NN denotes None
T720 62117-62132 NNS denotes Acknowledgments
T721 62133-62135 PRP denotes We
T722 62136-62141 VBP denotes thank
T723 62142-62148 NNP denotes Halina
T724 62149-62154 NNP denotes Trist
T725 62155-62158 IN denotes for
T726 62159-62169 NN denotes assistance
T727 62170-62174 IN denotes with
T728 62175-62178 DT denotes the
T729 62179-62189 NN denotes manuscript
T730 62191-62193 PRP denotes We
T731 62194-62198 RB denotes also
T732 62199-62204 VBP denotes thank
T733 62205-62210 NNP denotes NHMRC
T734 62210-62211 -COMMA- denotes ,
T735 62212-62218 NNP denotes Janina
T736 62219-62222 CC denotes and
T737 62223-62227 NNP denotes Bill
T738 62228-62233 NNP denotes Amiet
T739 62234-62239 NNP denotes Trust
T740 62239-62240 -COMMA- denotes ,
T741 62241-62249 NNP denotes Margaret
T742 62250-62256 NNP denotes Walkom
T743 62257-62262 NNP denotes Trust
T744 62263-62266 CC denotes and
T745 62267-62272 NNP denotes Nancy
T746 62273-62274 NNP denotes E
T747 62275-62285 NNP denotes Pendergast
T748 62286-62291 NNP denotes Trust
T749 62291-62292 -COMMA- denotes ,
T750 62293-62299 NNP denotes Genmab
T751 62299-62300 -COMMA- denotes ,
T752 62301-62304 IN denotes for
T753 62305-62310 PRP-DOLLAR- denotes their
T754 62311-62318 NN denotes support
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R10 T12 T10 arg1Of or,the
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R11 T11 T12 arg1Of “sweeping”,or
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R12 T13 T12 arg2Of removal,or
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R13 T12 T14 arg1Of or,of
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R14 T17 T14 arg2Of complexes,of
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R15 T17 T15 arg1Of complexes,small
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R16 T17 T16 arg1Of complexes,immune
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R17 T6 T18 arg1Of and,has
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R18 T19 T18 arg2Of opened,has
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R19 T6 T19 arg1Of and,opened
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R2 T3 T2 arg2Of FcγRIIb,of
R20 T22 T19 arg2Of possibilities,opened
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R21 T19 T20 arg1Of opened,up
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R22 T22 T21 arg1Of possibilities,new
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R23 T22 T23 arg1Of possibilities,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R24 T25 T23 arg2Of application,for
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R25 T25 T24 arg1Of application,the
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R26 T25 T26 arg1Of application,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R27 T30 T26 arg2Of or,of
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R29 T29 T28 arg1Of Antibodies,modifications.17
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R3 T1 T4 arg1Of expression,on
R30 T29 T30 arg1Of Antibodies,or
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R31 T33 T30 arg2Of proteins,or
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R32 T33 T31 arg1Of proteins,Fc
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R33 T33 T32 arg1Of proteins,fusion
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R34 T22 T34 arg1Of possibilities,","
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R35 T37 T35 arg1Of MOA,whose
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R36 T22 T35 arg2Of possibilities,whose
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","
R367 T358 T356 arg1Of Strategies,Future
R368 T358 T357 arg1Of Strategies,Engineering
R369 T360 T359 arg1Of antibodies,Monoclonal
R37 T37 T36 arg1Of MOA,primary
R370 T360 T361 arg1Of antibodies,are
R371 T363 T361 arg2Of therapeutics,are
R372 T363 T362 arg1Of therapeutics,potent
R373 T361 T364 arg1Of are,in
R374 T366 T364 arg2Of number,in
R375 T366 T365 arg1Of number,a
R376 T366 T367 arg1Of number,of
R377 T372 T367 arg2Of diseases,of
R378 T372 T368 arg1Of diseases,chronic
R379 T368 T369 arg1Of chronic,or
R38 T37 T38 arg1Of MOA,is
R380 T371 T369 arg2Of incurable,or
R381 T371 T370 arg1Of incurable,once
R382 T372 T371 arg1Of diseases,incurable
R383 T376 T373 arg1Of is,However
R384 T376 T374 arg1Of is,","
R385 T375 T376 arg1Of there,is
R386 T384 T376 arg2Of as,is
R387 T376 T377 arg1Of is,still
R388 T380 T378 arg1Of clinical,extensive
R389 T380 T379 arg1Of clinical,unmet
R39 T40 T38 arg2Of neutralization,is
R390 T381 T380 arg1Of need,clinical
R391 T384 T382 arg1Of as,as
R392 T384 T383 arg1Of as,well
R393 T381 T384 arg1Of need,as
R394 T386 T384 arg2Of room,as
R395 T386 T385 arg1Of room,considerable
R396 T386 T387 arg1Of room,for
R397 T388 T387 arg2Of improvement,for
R398 T388 T389 arg1Of improvement,in
R399 T392 T389 arg2Of therapeutics,in
R4 T5 T4 arg2Of LSEC,on
R40 T40 T39 arg1Of neutralization,the
R400 T392 T390 arg1Of therapeutics,many
R401 T392 T391 arg1Of therapeutics,existing
R402 T394 T393 arg1Of understanding,Further
R403 T394 T395 arg1Of understanding,of
R404 T396 T395 arg2Of how,of
R405 T399 T396 arg1Of affects,how
R406 T398 T397 arg1Of structure,antibody
R407 T398 T399 arg1Of structure,affects
R408 T401 T399 arg2Of function,affects
R409 T401 T400 arg1Of function,FcγR
R41 T40 T41 arg1Of neutralization,of
R410 T394 T402 arg1Of understanding,is
R411 T403 T402 arg2Of essential,is
R412 T394 T403 arg1Of understanding,essential
R413 T403 T404 arg1Of essential,for
R414 T406 T404 arg2Of development,for
R415 T406 T405 arg1Of development,future
R416 T406 T407 arg1Of development,of
R417 T412 T407 arg2Of mAbs,of
R418 T412 T408 arg1Of mAbs,more
R419 T412 T409 arg1Of mAbs,potent
R42 T43 T41 arg2Of molecules,of
R420 T409 T410 arg1Of potent,and
R421 T411 T410 arg2Of effective,and
R422 T412 T411 arg1Of mAbs,effective
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R43 T43 T42 arg1Of molecules,soluble
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R44 T45 T44 arg1Of as,such
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R45 T43 T45 arg1Of molecules,as
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R46 T47 T45 arg2Of or,as
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R47 T46 T47 arg1Of IgE,or
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R48 T48 T47 arg2Of cytokines,or
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R49 T38 T49 arg1Of is,","
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R5 T1 T6 arg1Of expression,and
R50 T50 T49 arg2Of are,","
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R51 T37 T50 arg1Of MOA,are
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement
R517 T514 T503 arg1Of suggests,Furthermore
R518 T514 T504 arg1Of suggests,","
R519 T508 T505 arg1Of nature,the
R52 T53 T50 arg2Of candidates,are
R520 T508 T506 arg1Of nature,mixed
R521 T508 T507 arg1Of nature,subclass
R522 T508 T509 arg1Of nature,of
R523 T513 T509 arg2Of responses,of
R524 T513 T510 arg1Of responses,these
R525 T513 T511 arg1Of responses,normal
R526 T513 T512 arg1Of responses,antibody
R527 T508 T514 arg1Of nature,suggests
R528 T518 T514 arg2Of arise,suggests
R529 T518 T515 arg1Of arise,that
R53 T52 T51 arg1Of attractive,particularly
R530 T516 T517 arg1Of circumstances,may
R531 T518 T517 arg2Of arise,may
R532 T516 T518 arg1Of circumstances,arise
R533 T518 T519 arg1Of arise,in
R534 T521 T519 arg2Of strategies,in
R535 T521 T520 arg1Of strategies,therapeutic
R536 T521 T522 arg1Of strategies,where
R537 T524 T522 arg2Of is,where
R538 T523 T524 arg1Of there,is
R539 T525 T524 arg2Of value,is
R54 T53 T52 arg1Of candidates,attractive
R540 T525 T526 arg1Of value,in
R541 T527 T526 arg2Of having,in
R542 T530 T527 arg2Of Fcs,having
R543 T530 T528 arg1Of Fcs,distinctly
R544 T530 T529 arg2Of Fcs,modified
R545 T530 T531 arg1Of Fcs,for
R546 T534 T531 arg2Of engagement,for
R547 T534 T532 arg1Of engagement,the
R548 T534 T533 arg1Of engagement,nuanced
R549 T534 T535 arg1Of engagement,of
R55 T53 T54 arg1Of candidates,for
R550 T539 T535 arg2Of members,of
R551 T539 T536 arg1Of members,different
R552 T539 T537 arg1Of members,FcγR
R553 T539 T538 arg1Of members,family
R554 T540 T541 arg1Of Treatments,comprising
R555 T544 T541 arg2Of and,comprising
R556 T543 T542 arg1Of mAbs,multiple
R557 T543 T544 arg1Of mAbs,and
R558 T546 T544 arg2Of stimulants,and
R559 T546 T545 arg1Of stimulants,immune
R56 T56 T54 arg2Of approach,for
R560 T540 T547 arg1Of Treatments,are
R561 T548 T547 arg2Of under,are
R562 T540 T548 arg1Of Treatments,under
R563 T549 T548 arg2Of investigation,under
R564 T547 T550 arg1Of are,in
R565 T552 T550 arg2Of disease,in
R566 T552 T551 arg1Of disease,infectious
R567 T552 T553 arg1Of disease,for
R568 T555 T553 arg2Of coverage,for
R569 T555 T554 arg1Of coverage,neutralization
R57 T56 T55 arg1Of approach,this
R570 T555 T556 arg1Of coverage,of
R571 T558 T556 arg2Of strains,of
R572 T558 T557 arg1Of strains,variant
R573 T565 T559 arg1Of be,Indeed
R574 T565 T560 arg1Of be,","
R575 T563 T561 arg1Of approach,such
R576 T563 T562 arg1Of approach,an
R577 T563 T564 arg1Of approach,may
R578 T565 T564 arg2Of be,may
R579 T563 T565 arg1Of approach,be
R58 T57 T58 arg1Of Proof‐of‐concept,for
R580 T567 T565 arg2Of effective,be
R581 T567 T566 arg1Of effective,most
R582 T563 T567 arg1Of approach,effective
R583 T567 T568 arg1Of effective,in
R584 T569 T568 arg2Of emerging,in
R585 T571 T569 arg2Of disease,emerging
R586 T571 T570 arg1Of disease,infectious
R587 T573 T572 arg1Of as,such
R588 T571 T573 arg1Of disease,as
R589 T583 T573 arg2Of infection,as
R59 T60 T58 arg2Of strategy,for
R590 T576 T574 arg1Of respiratory,severe
R591 T576 T575 arg1Of respiratory,acute
R592 T583 T576 arg1Of infection,respiratory
R593 T583 T577 arg1Of infection,syndrome
R594 T583 T578 arg1Of infection,coronavirus
R595 T583 T579 arg1Of infection,2
R596 T583 T580 arg1Of infection,(
R597 T581 T580 arg2Of SARS‐CoV‐2,(
R598 T582 T580 arg3Of ),(
R599 T585 T584 arg1Of use,The
R6 T8 T6 arg2Of action,and
R60 T60 T59 arg1Of strategy,this
R600 T585 T586 arg1Of use,of
R601 T588 T586 arg2Of mAbs,of
R602 T588 T587 arg1Of mAbs,multiple
R603 T588 T589 arg2Of mAbs,tailored
R604 T589 T590 arg1Of tailored,for
R605 T593 T590 arg2Of functions,for
R606 T593 T591 arg1Of functions,distinct
R607 T593 T592 arg1Of functions,effector
R608 T589 T594 arg1Of tailored,and
R609 T595 T594 arg2Of targeting,and
R61 T57 T61 arg1Of Proof‐of‐concept,has
R610 T588 T595 arg1Of mAbs,targeting
R611 T597 T595 arg2Of epitopes,targeting
R612 T597 T596 arg1Of epitopes,different
R613 T585 T598 arg1Of use,will
R614 T599 T598 arg2Of maximize,will
R615 T585 T599 arg1Of use,maximize
R616 T601 T599 arg2Of opportunity,maximize
R617 T601 T600 arg1Of opportunity,the
R618 T601 T602 arg1Of opportunity,for
R619 T603 T602 arg2Of cocktailing,for
R62 T63 T61 arg2Of demonstrated,has
R620 T603 T604 arg1Of cocktailing,of
R621 T606 T604 arg2Of functions,of
R622 T606 T605 arg1Of functions,effector
R623 T599 T607 arg1Of maximize,in
R624 T609 T607 arg2Of types,in
R625 T609 T608 arg1Of types,different
R626 T609 T610 arg1Of types,of
R627 T611 T610 arg2Of diseases,of
R628 T631 T612 arg1Of uses,Indeed
R629 T631 T613 arg1Of uses,","
R63 T57 T62 arg1Of Proof‐of‐concept,been
R630 T631 T614 arg1Of uses,in
R631 T619 T614 arg2Of example,in
R632 T619 T615 arg1Of example,a
R633 T619 T616 arg1Of example,small
R634 T616 T617 arg1Of small,but
R635 T618 T617 arg2Of contemporary,but
R636 T619 T618 arg1Of example,contemporary
R637 T619 T620 arg1Of example,outside
R638 T620 T621 arg1Of outside,of
R639 T623 T621 arg2Of disease,of
R64 T63 T62 arg2Of demonstrated,been
R640 T623 T622 arg1Of disease,infectious
R641 T631 T624 arg1Of uses,","
R642 T627 T625 arg1Of combination,the
R643 T627 T626 arg1Of combination,FDA‐approved
R644 T627 T628 arg1Of combination,in
R645 T630 T628 arg2Of therapy,in
R646 T630 T629 arg1Of therapy,adenocarcinoma
R647 T627 T631 arg1Of combination,uses
R648 T633 T631 arg2Of cocktail,uses
R649 T633 T632 arg1Of cocktail,a
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R650 T633 T634 arg1Of cocktail,of
R651 T636 T634 arg2Of mAbs,of
R652 T636 T635 arg1Of mAbs,two
R653 T633 T637 arg1Of cocktail,","
R654 T639 T637 arg2Of and,","
R655 T638 T639 arg1Of pertuzumab,and
R656 T640 T639 arg2Of trastuzumab,and
R657 T631 T641 arg1Of uses,","
R658 T631 T642 arg1Of uses,against
R659 T643 T642 arg2Of Her2.123,against
R66 T63 T64 arg1Of demonstrated,in
R660 T674 T644 arg1Of utilize,Rather
R661 T644 T645 arg1Of Rather,than
R662 T647 T645 arg2Of type,than
R663 T647 T646 arg1Of type,one
R664 T647 T648 arg1Of type,of
R665 T649 T648 arg2Of Fc,of
R666 T651 T650 arg1Of conquer,to
R667 T647 T650 modOf type,to
R668 T652 T651 arg2Of all,conquer
R669 T674 T653 arg1Of utilize,","
R67 T66 T64 arg2Of models.48,in
R670 T656 T654 arg1Of use,the
R671 T656 T655 arg1Of use,combined
R672 T656 T657 arg1Of use,of
R673 T660 T657 arg2Of mAbs,of
R674 T659 T658 arg1Of selected,appropriately
R675 T660 T659 arg1Of mAbs,selected
R676 T663 T661 arg1Of components,whose
R677 T660 T661 arg2Of mAbs,whose
R678 T663 T662 arg1Of components,individual
R679 T663 T664 arg1Of components,are
R68 T66 T65 arg1Of models.48,experimental
R680 T665 T664 arg2Of enhanced,are
R681 T663 T665 arg2Of components,enhanced
R682 T665 T666 arg1Of enhanced,for
R683 T668 T666 arg2Of engagement,for
R684 T668 T667 arg1Of engagement,the
R685 T668 T669 arg1Of engagement,of
R686 T672 T669 arg2Of members,of
R687 T672 T670 arg1Of members,different
R688 T672 T671 arg1Of members,FcγR
R689 T656 T673 arg1Of use,may
R69 T66 T67 arg1Of models.48,Indeed
R690 T674 T673 arg2Of utilize,may
R691 T656 T674 arg1Of use,utilize
R692 T676 T674 arg2Of components,utilize
R693 T676 T675 arg1Of components,multiple
R694 T676 T677 arg1Of components,of
R695 T679 T677 arg2Of spectrum,of
R696 T679 T678 arg1Of spectrum,the
R697 T679 T680 arg1Of spectrum,of
R698 T682 T680 arg2Of responses,of
R699 T682 T681 arg1Of responses,effector
R7 T8 T7 arg1Of action,its
R70 T63 T68 arg1Of demonstrated,","
R700 T679 T683 arg1Of spectrum,on
R701 T684 T683 arg2Of offer,on
R702 T674 T685 arg1Of utilize,by
R703 T688 T685 arg2Of system,by
R704 T688 T686 arg1Of system,the
R705 T688 T687 arg1Of system,immune
R706 T691 T689 arg1Of biologics,Such
R707 T691 T690 arg1Of biologics,“next‐gen”
R708 T691 T692 arg1Of biologics,will
R709 T693 T692 arg2Of begin,will
R71 T71 T68 arg2Of be,","
R710 T691 T693 arg1Of biologics,begin
R711 T704 T693 arg2Of and,begin
R712 T704 T694 arg1Of and,to
R713 T691 T695 arg1Of biologics,realize
R714 T698 T695 arg2Of potential,realize
R715 T698 T696 arg1Of potential,the
R716 T698 T697 arg1Of potential,full
R717 T698 T699 arg1Of potential,of
R718 T703 T699 arg2Of therapeutics,of
R719 T703 T700 arg1Of therapeutics,FcγR‐mediated
R72 T69 T70 arg1Of this,may
R720 T703 T701 arg1Of therapeutics,antibody
R721 T703 T702 arg1Of therapeutics,immune
R722 T695 T704 arg1Of realize,and
R723 T705 T704 arg2Of offer,and
R724 T691 T705 arg1Of biologics,offer
R725 T707 T705 arg2Of change,offer
R726 T707 T706 arg1Of change,transformational
R727 T705 T708 arg1Of offer,for
R728 T710 T708 arg2Of treatment,for
R729 T710 T709 arg1Of treatment,the
R73 T71 T70 arg2Of be,may
R730 T710 T711 arg1Of treatment,of
R731 T715 T711 arg2Of diseases,of
R732 T715 T712 arg1Of diseases,intractable
R733 T712 T713 arg1Of intractable,and
R734 T714 T713 arg2Of incurable,and
R735 T715 T714 arg1Of diseases,incurable
R736 T716 T717 arg1Of Conflict,of
R737 T718 T717 arg2Of Interest,of
R738 T721 T722 arg1Of We,thank
R739 T724 T722 arg2Of Trist,thank
R74 T69 T71 arg1Of this,be
R740 T724 T723 arg1Of Trist,Halina
R741 T722 T725 arg1Of thank,for
R742 T726 T725 arg2Of assistance,for
R743 T726 T727 arg1Of assistance,with
R744 T729 T727 arg2Of manuscript,with
R745 T729 T728 arg1Of manuscript,the
R746 T732 T731 arg1Of thank,also
R747 T730 T732 arg1Of We,thank
R748 T749 T732 arg2Of ",",thank
R749 T733 T734 arg1Of NHMRC,","
R75 T74 T71 arg2Of component,be
R750 T735 T734 arg2Of Janina,","
R751 T734 T736 arg1Of ",",and
R752 T739 T736 arg2Of Trust,and
R753 T739 T737 arg1Of Trust,Bill
R754 T739 T738 arg1Of Trust,Amiet
R755 T736 T740 arg1Of and,","
R756 T743 T740 arg2Of Trust,","
R757 T743 T741 arg1Of Trust,Margaret
R758 T743 T742 arg1Of Trust,Walkom
R759 T740 T744 arg1Of ",",and
R76 T74 T72 arg1Of component,a
R760 T748 T744 arg2Of Trust,and
R761 T748 T745 arg1Of Trust,Nancy
R762 T748 T746 arg1Of Trust,E
R763 T748 T747 arg1Of Trust,Pendergast
R764 T744 T749 arg1Of and,","
R765 T750 T749 arg2Of Genmab,","
R766 T732 T751 arg1Of thank,","
R767 T732 T752 arg1Of thank,for
R768 T754 T752 arg2Of support,for
R769 T754 T753 arg1Of support,their
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R8 T8 T9 arg1Of action,in
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R9 T12 T9 arg2Of or,in
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”